Research · 2026-02-26
First Documented Case: Mitragynine Pseudoindoxyl Withdrawal Successfully Treated with Buprenorphine Macro-Induction
Source: Preprints.org (MDPI)
Why it matters
Mitragynine pseudoindoxyl (MP) is a semi-synthetic kratom compound increasingly sold as "kratom" or "7-OH" with no FDA approval and no prior human safety data — and until now, no documented treatment protocol for its withdrawal.
The big picture
Mitragynine pseudoindoxyl is a semi-synthetic derivative of kratom alkaloids that has begun appearing in over-the-counter and online products mislabeled as natural kratom or 7-OH. Unlike natural kratom leaf, MP has never been tested in humans for safety. As concentrated synthetic kratom products proliferate, clinicians in emergency departments and addiction programs are encountering withdrawal cases they are unprepared to manage, since standard opioid withdrawal protocols may be insufficient for these novel compounds.
Key findings
- A 44-year-old male using 400 mg of mitragynine pseudoindoxyl daily for pain management developed moderate opioid-like withdrawal symptoms upon cessation
- Clinicians initiated a buprenorphine macro-induction protocol: 32 mg of buprenorphine (16 mg × 2) on day one, with maintenance dosing and adjunctive medications
- Chlorpromazine was used as an anti-emetic and diazepam addressed concurrent alcohol withdrawal
- The patient's COWS (Clinical Opioid Withdrawal Scale) scores improved significantly and he expressed interest in long-acting injectable buprenorphine maintenance
- This is reported as the first documented successful management of MP-specific withdrawal in the medical literature
- Authors note that MP products are often falsely marketed as natural kratom, complicating clinical assessment
What they say
The case report authors write that this "represents the first documented case of MP withdrawal successfully managed with buprenorphine macro-induction, demonstrating the potential efficacy of this approach for novel semi-synthetic kratom metabolites when standard withdrawal management protocols are insufficient."
Bottom line
Clinicians encountering kratom withdrawal should be alert to mitragynine pseudoindoxyl as a distinct and more potent semi-synthetic compound — and this first case report suggests buprenorphine macro-induction can work when standard protocols fall short.